Skip to main content
Premium Trial:

Request an Annual Quote

Genentech Exec Joins Axys Pharmaceuticals

Premium

SOUTH SAN FRANCISCO, Calif.--Axys Pharmaceuticals announced that John Wulf, formerly director of business development for Genentech, where he was employed for 17 years, has joined Axys as vice-president of business development. Wulf will manage business development in areas of genomics and small-molecule drug development. He reports directly to Daniel Petree, CEO of the life sciences firm here. Petree said Wulf's background will be an asset to Axys as the company expands its efforts toward broad collaborations in inflammatory diseases, metabolic disorders, and oncology.

Filed under

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.